{"id":6465,"date":"2024-03-11T10:43:51","date_gmt":"2024-03-11T08:43:51","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?page_id=6465"},"modified":"2024-03-11T10:43:51","modified_gmt":"2024-03-11T08:43:51","slug":"vaxneuvance-publication-of-clinical-trial-results","status":"publish","type":"page","link":"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/","title":{"rendered":"VAXNEUVANCE &#8211; Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques<\/h1>\n\n\n\n<p>Les informations ci-dessous ainsi que les liens correspondant aux donn\u00e9es cliniques r\u00e9pondent aux exigences des articles 71 \u00e0 73 de l\u2019Ordonnance sur les m\u00e9dicaments (Ordonnance sur les m\u00e9dicaments, OM\u00e9d) et compl\u00e8tent les informations publi\u00e9es en lien avec l\u2019autorisation suisse des m\u00e9dicaments correspondants.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">VAXNEUVANCE\u00ae<\/h2>\n\n\n\n<p>Vaccin pneumococcique polyosidique conjugu\u00e9 (15-valent, adsorb\u00e9). Solution injectable.<\/p>\n\n\n\n<p>1 dose (0,5 ml) contient:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Polyoside pneumococcique de s\u00e9rotype 1<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 3<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 4<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 5<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 6A<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 6B<sup>1,2<\/sup> 4,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 7F<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 9V<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 14<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 18C<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 19A<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 19F<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 22F<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 23F<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n\n\n\n<li>Polyoside pneumococcique de s\u00e9rotype 33F<sup>1,2<\/sup> 2,0 microgrammes<\/li>\n<\/ul>\n\n\n\n<p class=\"has-small-font-size\"><sup>1&nbsp;<\/sup>Conjugu\u00e9 \u00e0 la prot\u00e9ine vectrice CRM<sub>197<\/sub>. La prot\u00e9ine CRM<sub>197<\/sub> est une toxine dipht\u00e9rique mutante non toxique <em>(issue de Corynebacterium diphtheriae C7)<\/em> exprim\u00e9e par recombinaison dans <em>Pseudomonas fluorescens<\/em>. <br><sup>2&nbsp;<\/sup>Adsorb\u00e9 sur phosphate d&#8217;aluminium utilis\u00e9 comme adjuvant.<\/p>\n\n\n\n<p class=\"has-small-font-size\">1&nbsp;dose (0,5&nbsp;ml) contient 125&nbsp;microgrammes d&#8217;aluminium (Al<sup>3+<\/sup>) et environ 30&nbsp;microgrammes de prot\u00e9ine vectrice CRM<sub>197<\/sub>.<\/p>\n\n\n\n<p>Num\u00e9ro d\u2019autorisation: 68752<\/p>\n\n\n\n<p>Swissmedic Date d&#8217;autorisation: 14 f\u00e9vrier 2023<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br><strong>\u00c9tudes cliniques<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03950622?term=v114&amp;draw=4&amp;rank=8\">Safety and Immunogenicity of V114 in Healthy Adults (V114-019\/PNEU-AGE) &#8211; ClinicalTrials.gov<\/a><br>NCT03950622<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022 Jan 3;40(1):162-172. doi: 10.1016\/j.vaccine.2021.08.049. Epub 2021 Sep 8. PMID: 34507861.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480763?term=v114&amp;draw=3&amp;rank=16\">A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX\u212223 in Healthy Adults 50 Years of Age or Older (V114-016\/PNEU-PATH) &#8211; ClinicalTrials.gov<\/a><br>NCT03480763<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Song JY, Chang CJ, Andrews C, Diez-Domingo J, Oh MD, Dagan R, Hartzel J, Pedley A, Li J, Sterling T, Tamms G, Chiarappa JA, Lutkiewicz J, Musey L, Tu Y, Buchwald UK; V114-016 (PNEU-PATH) study group. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged\u202f\u226550\u202fyears: A randomized phase III trial (PNEU-PATH). Vaccine. 2021 Oct 15;39(43):6422-6436. doi: 10.1016\/j.vaccine.2021.08.038. Epub 2021 Sep 4. PMID: 34489128.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02573181?term=v114&amp;draw=3&amp;rank=14\">Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13\u2122 in PPSV23-vaccinated Healthy Adults \u226565 Years of Age (V114-007) &#8211; ClinicalTrials.gov<\/a><br>NCT02573181<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540-548. doi: 10.1080\/21645515.2018.1532250. Epub 2018 Nov 14. PMID: 30427749; PMCID: PMC6605723.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03615482?term=v114&amp;draw=3&amp;rank=19\">A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021\/PNEU-FLU) &#8211; ClinicalTrials.gov<\/a><br>NCT03615482<\/p>\n\n\n\n<p><strong>Publication:<\/strong> <br>Severance R, Schwartz H, Dagan R, Connor L, Li J, Pedley A, Hartzel J, Sterling TM, Nolan KM, Tamms GM, Musey LK, Buchwald UK. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged \u226550 years: a randomized phase 3 trial (PNEU-FLU). Hum Vaccin Immunother. 2022 Dec 31;18(1):1-14. doi: 10.1080\/21645515.2021.1976581. Epub 2021 Nov 2. PMID: 34726574; PMCID: PMC8920144.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br><strong>Extension p\u00e9diatrique<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03885934?cond=Pneumococcal%20Infections&amp;intr=Vaccination&amp;titles=A%20Phase%203,%20Multicenter,%20Randomized,%20Double-blind,%20Active%20Comparator-controlled%20Study%20to%20Evaluate%20the%20Safety,%20Tolerability,%20and%20Immunogenicity%20of%20Catch-up%20Vaccination%20Regimens%20of%20V114%20in%20Healthy%20Infants,%20Children,%20and%20Adolescents%20(PNEU-%20PLAN)&amp;aggFilters=ages:child&amp;rank=1\">A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU-PLAN)<\/a><br>NCT03885934<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Banniettis N, Wysocki J, Szenborn L, Phongsamart W, Pitisuttithum P, Ramet M, Richmond P, Shi Y, Dagan R, Good L, Papa M, Lupinacci R, McFetridge R, Tamms G, Churchill C, Musey L, Bickham K; V114-024 PNEU-PLAN study group. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine. 2022 Oct 19;40(44):6315-6325. doi: 10.1016\/j.vaccine.2022.09.003. Epub 2022 Sep 21.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04031846?cond=Pneumococcal%20Infections&amp;intr=Vaccination&amp;titles=A%20phase%203,%20multicenter,%20randomized,%20double-blind,%20active-comparator-controlled%20study%20to%20evaluate%20the%20safety,%20tolerability,%20and%20immunogenicity%20of%20a%204-dose%20regimen%20of%20V114,%20a%2015-valent%20pneumococcal%20conjugate%20vaccine,%20in%20healthy%20infants%20(PNEU-PED)&amp;aggFilters=ages:child&amp;id=NCT04031846&amp;rank=1\">A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)<\/a><br>NCT04031846<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Martinon-Torres F, Wysocki J, Szenborn L, Carmona-Martinez A, Poder A, Dagan R, Richmond P, Gilbert C, Trudel MC, Flores S, Lupinacci R, McFetridge R, Wiedmann RT, Chen Q, Gerrits H, Banniettis N, Musey L, Bickham K, Kaminski J; V114-025 PNEU-PED-EU-1 study group. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023 May 16;41(21):3387-3398. doi: 10.1016\/j.vaccine.2023.04.036. Epub 2023 Apr 25. PMID: 37105892<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03620162?cond=Pneumococcal%20Infections&amp;intr=Vaccination&amp;titles=A%20Phase%203,%20Multicenter,%20Randomized,%20Double-blind%20Study%20to%20Evaluate%20the%20Interchangeability%20of%20V114%20and%20Prevnar%2013%E2%84%A2%20with%20Respect%20to%20Safety,%20Tolerability,%20and%20Immunogenicity%20in%20Healthy%20Infants%20(PNEU-DIRECTION)&amp;aggFilters=ages:child&amp;rank=1#study-overview\">A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)<\/a><br>NCT03620162<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, Dagan R, Richmond P, Wilck M, Vallejos W, Nunn C, McFetridge R, Tamms G, Fu R, Lupinacci R, Musey L, Banniettis N, Bickham K; V114-027 PNEU-DIRECTION study group. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine. 2023 Jan 16;41(3):657-665. doi: 10.1016\/j.vaccine.2022.10.072. Epub 2022 Dec 13. PMID: 36522265<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03893448?cond=Pneumococcal%20Infections&amp;intr=Vaccination&amp;titles=A%20Phase%203,%20Multicenter,%20Randomized,%20Double-blind,%20Active-Comparator-controlled%20Study%20to%20Evaluate%20the%20Safety,%20Tolerability,%20and%20Immunogenicity%20of%20a%204-dose%20Regimen%20of%20V114%20in%20Healthy%20Infants%20(PNEU-PED)&amp;aggFilters=ages:child&amp;rank=1\">A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 dose Regimen of V114 in Healthy Infants (PNEU-PED)<\/a><br>NCT03893448<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, Dagan R, Richmond P, Stek JE, Romero L, Koseoglu S, Tamms G, McFetridge R, Li J, Cheon K, Musey L, Banniettis N, Bickham K; V114-029 PNEU-PED study group. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023 Jan 27;41(5):1142-1152. doi: 10.1016\/j.vaccine.2022.12.054. Epub 2023 Jan 6. PMID: 36621410<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03692871?cond=Pneumococcal%20Infections&amp;intr=Vaccination&amp;titles=A%20Phase%203,%20Multicenter,%20Randomized,%20Double-blind,%20Active%20Comparator-controlled%20Study%20to%20Evaluate%20the%20Safety%20and%20Tolerability%20of%20V114%20in%20Healthy%20Infants%20(PNEU-LINK)&amp;aggFilters=ages:child&amp;rank=1\">A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)<\/a><br>NCT03692871<\/p>\n\n\n\n<p><strong>Publication:<\/strong><br>Banniettis N, Horn M, Sadarangani M, Patel SM, Greenberg D, Oberdorfer P, Klein NP, Rupp R, Dagan R, Richmond P, Lumley J, Zhou W, Shi Y, Tamms G, Feemster K, Lupinacci R, Musey L, Bickham K; V114-031 (PNEU-LINK) study group. Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study. Pediatrics. 2023 Jul 1;152(1):e2022060428. doi: 10.1542\/peds.2022-060428. PMID: 37309607<\/p>\n\n\n\n<p><sup>CH-PVC-00033, 03\/2024<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques Les informations ci-dessous ainsi que les liens correspondant aux donn\u00e9es cliniques r\u00e9pondent aux exigences des articles 71 \u00e0 73 de l\u2019Ordonnance sur les m\u00e9dicaments (Ordonnance sur les m\u00e9dicaments, OM\u00e9d) et compl\u00e8tent les informations publi\u00e9es en lien avec l\u2019autorisation suisse des m\u00e9dicaments correspondants. VAXNEUVANCE\u00ae Vaccin pneumococcique polyosidique conjugu\u00e9 (15-valent, adsorb\u00e9). Solution [&hellip;]<\/p>\n","protected":false},"author":282,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"editor_notices":[],"footnotes":""},"class_list":["post-6465","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch<\/title>\n<meta name=\"description\" content=\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch\" \/>\n<meta property=\"og:description\" content=\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/\",\"url\":\"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/\",\"name\":\"VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\"},\"datePublished\":\"2024-03-11T08:43:51+00:00\",\"dateModified\":\"2024-03-11T08:43:51+00:00\",\"description\":\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\",\"url\":\"https:\/\/www.msd.ch\/fr\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/","og_locale":"en_US","og_type":"article","og_title":"VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","og_description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.","og_url":"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/","url":"https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/","name":"VAXNEUVANCE - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2024-03-11T08:43:51+00:00","dateModified":"2024-03-11T08:43:51+00:00","description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur VAXNEUVANCE vaccin pneumococcique polysaccharidique conjugu\u00e9 (15-valent, adsorb\u00e9), suspension injectable, autoris\u00e9e par Swissmedic le 14 f\u00e9vrier 2023.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/fr\/vaxneuvance-publication-of-clinical-trial-results\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/6465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/users\/282"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/comments?post=6465"}],"version-history":[{"count":4,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/6465\/revisions"}],"predecessor-version":[{"id":7375,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/6465\/revisions\/7375"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=6465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}